KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Non-Current Deferred Tax Liability (2016 - 2019)

Arbutus Biopharma's Non-Current Deferred Tax Liability history spans 5 years, with the latest figure at $12.7 million for Q2 2019.

  • On a quarterly basis, Non-Current Deferred Tax Liability fell 25.27% to $12.7 million in Q2 2019 year-over-year; TTM through Jun 2019 was $12.7 million, a 25.27% decrease, with the full-year FY2018 number at $12.7 million, down 25.27% from a year prior.
  • Non-Current Deferred Tax Liability hit $12.7 million in Q2 2019 for Arbutus Biopharma, roughly flat from $12.7 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for ABUS hit a ceiling of $156.0 million in Q2 2015 and a floor of $12.7 million in Q3 2018.
  • Historically, Non-Current Deferred Tax Liability has averaged $60.0 million across 5 years, with a median of $41.3 million in 2016.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: plummeted 71.8% in 2016 and later fell 25.27% in 2018.
  • Tracing ABUS's Non-Current Deferred Tax Liability over 5 years: stood at $146.3 million in 2015, then plummeted by 71.8% to $41.3 million in 2016, then crashed by 58.94% to $16.9 million in 2017, then fell by 25.27% to $12.7 million in 2018, then changed by 0.0% to $12.7 million in 2019.
  • Business Quant data shows Non-Current Deferred Tax Liability for ABUS at $12.7 million in Q2 2019, $12.7 million in Q1 2019, and $12.7 million in Q4 2018.